Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo

Nucleic acid therapeutics have been utilized for gene regulation, and their recent advancement has led to approval of novel drugs for liver-related disorders. However, systemic extrahepatic delivery remains challenging. Here, we report newly designed mannose-conjugated Oligonucleotides for delivering Oligonucleotides to macrophages by leveraging the Mannose Receptor, C-type 1 (MRC1, CD206), which is abundantly expressed in macrophages. We investigated the relationship between cellular uptake and multivalency (mono to tetra) of mannose ligands or linker length and selected a trivalent-mannose ligand. Trivalent-mannose (Man3)-conjugated siRNA induced concentration-dependent gene silencing in both human CD206-overexpressing cells and human macrophages in vitro. After subcutaneous injection into mice, we observed a high distribution of Man3-conjugated Oligonucleotides in the liver and pancreata as well as cellular uptake into Kupffer cells and pancreatic macrophages. A single subcutaneous injection of Man3-conjugated siRNA (10 mg/kg) targeting β₂-microglobulin (B2M) silenced B2m mRNA expression by ∼ 50% and decreased its protein levels in mouse pancreatic macrophages compared to those in saline-treated mice. Of note, multiple subcutaneous injections decreased B2m gene expression and B2M protein levels by ∼ 80% and ∼ 85%, respectively. These results show that mannose-conjugation with Oligonucleotides is expected to help deliver Oligonucleotides to macrophages and regulate gene expression in vivo, particularly in the pancreas.

CD206; Macrophages; Mannose ligands; Nucleic acid therapeutics; Pancreas.